Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 mill...

Descripción completa

Detalles Bibliográficos
Autores principales: Ustianowski, Andrew, Arends, Joop E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471058/
https://www.ncbi.nlm.nih.gov/pubmed/26032649
http://dx.doi.org/10.1007/s40121-015-0070-1
_version_ 1782376838487605248
author Ustianowski, Andrew
Arends, Joop E.
author_facet Ustianowski, Andrew
Arends, Joop E.
author_sort Ustianowski, Andrew
collection PubMed
description Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40121-015-0070-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4471058
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-44710582015-06-18 Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use Ustianowski, Andrew Arends, Joop E. Infect Dis Ther Review Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40121-015-0070-1) contains supplementary material, which is available to authorized users. Springer Healthcare 2015-06-02 2015-06 /pmc/articles/PMC4471058/ /pubmed/26032649 http://dx.doi.org/10.1007/s40121-015-0070-1 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Review
Ustianowski, Andrew
Arends, Joop E.
Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
title Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
title_full Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
title_fullStr Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
title_full_unstemmed Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
title_short Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
title_sort tenofovir: what we have learnt after 7.5 million person-years of use
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471058/
https://www.ncbi.nlm.nih.gov/pubmed/26032649
http://dx.doi.org/10.1007/s40121-015-0070-1
work_keys_str_mv AT ustianowskiandrew tenofovirwhatwehavelearntafter75millionpersonyearsofuse
AT arendsjoope tenofovirwhatwehavelearntafter75millionpersonyearsofuse

Ejemplares similares